Voyager Therapeutics (VYGR) Reports Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Tweet Send to a Friend
Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced positive longer-term results from the open-label, dose-escalating Phase 1b trial of VY-AADC demonstrating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
